Managing antipsychotic-induced tardive dyskinesia

Drug Safety

Volumn 20, Issue 2, 1999, Pages 187-193

  Gardos, George ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; NEUROLEPTIC AGENT;

AKATHISIA; DISEASE SEVERITY; DYSTONIA; HUMAN; LONG TERM CARE; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; RATING SCALE; REVIEW; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS;

EID: 0033022043     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920020-00007     Document Type: Review

References (24)

1. Casey D, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment. In: Banner J, Belmaker RH, editors. New directions in tardive dyskinesia research. Basel: Karger, 1983: 65-79
2. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991; 11: 34-42
3. Kane JM, Woerner M, Borenstern M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254-8
4. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995; 52: 756-65
5. Gardos G, Cole JO. The evaluation and treatment of neuroleptic-induced movement disorders. Harv Rev Psychiatry 1995; 3: 130-9
6. Guy W. ECDEU assessment manual for psychopharmacology. Rev. ed. Washington (DC): Department of Health, Education and Welfare, 1976
7. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982; 9: 486-7
8. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151: 836-41
9. Cole JO, Samson JA, Wykoff W, et al. Tardive dyskinesia: predictors of course over five years [poster]. Annual Meeting of the American Psychiatric Association. 1998 May. Toronto (ON)
10. Chouinard G, Annable L, Ross-Chouinard A. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8 (4 Suppl.): 21S-6S
11. Jeste DV, Lohr JB, Clark K, et al. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988; 8 (4 Suppl.): 38S-48S
12. Kane JM, Jeste DV, Barnes TRE, et al. editors, Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992
13. Gardos G, Cole JO. The treatment of tardive dyskinesias, In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1503-11
14. Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol plus biperiden, thioridazine, and clozapine. Psychopharmacology 1978; 59: 105-12
15. Alphs LD, Davis JM. Cholinergic treatments for tardive dyskinesia. In: Bannet J, Belmaker RH, editors. New directions in tardive dyskinesia research: modern problems in pharmacopsychiatry. Vol. 21. Basel: Karger, 1983; 168-86
16. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York, Guildford Press, 1982
17. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: 547-53
18. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503-10
19. Fleischhaker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994; 55 Suppl. B: 78-81
20. Szymanski S, Maune R, Gordon MF, et al. A selective review of recent advances in the management of tardive dyskinesia. Psychiatr Ann 1993; 23: 209-15
21. Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997; 20: 90-3
22. Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York, Futura, 1992; 167-98
23. Chen C-H, Wei F-C, Koong F-J, et al. Association of Tag I polymorphism of dopamine. D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41: 827-9
24. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139-45.